Press release from Companies
Publicerat: 2019-05-21 09:25:53
SCANDION ONCOLOGY A/S is pleased to announce that the company has received an “Intention to Grant” notice from the EPO regarding its European patent application 17726573.3, which includes SCO-101 in combination with specific topoisomerase I inhibitors to treat various cancers. The patent will last until 2037.
CEO Nils Brünner comments:
It is of significant importance that Scandion Oncology now obtains its first patent on its lead drug SCO-101 in the treatment of drug resistant cancer. We have filed additional patents on SCO-101 and are awaiting feedback on these applications.
For further information regarding Scandion Oncology, please contact:
Nils Brünner, CEO
Phone: +45 26 14 47 08
E-mail: nb@scandiononcology.com
This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on May 21, 2018.
Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical animal studies, the company’s leading candidate drug, SCO-101, was found to significantly enhance the efficacy of certain standard cancer treatments when given in combination. In addition, SCO-101 restores chemotherapy sensitivity in in vitro grown resistant cancer cells. Scandion Oncology will in Q4 2019 initiate a clinical phase II study with SCO-101 in combination with chemotherapy. Scandion Oncology was listed on Spotlight, Sweden in November 2018.
